News & Events
Published On: 12/18/2020
Target RWE Virtual Posters at Annual AIBD, RAD Conferences
In December 2020, Target RWE participated in two virtual conference events to highlight accepted abstract posters- Advances in Inflammatory Bowel Disease (AIBD) and Revolutionizing Atopic Dermatitis (RAD) Conference. The accepted abstract posters highlighted details and information from the ongoing Target RWE observational studies, TARGET-IBD and TARGET-DERM.
The TARGET-IBD poster accepted to AIBD titled ‘Factors Associated with Biologic Discontinuation in Patients with Inflammatory Bowel Disease in TARGET-IBD’ focuses on better understanding patterns of treatment discontinuation in real-world management of patients with inflammatory bowel disease (IBD). The analysis found that nearly 1/3 of the TARGET-IBD patients initiating biologic therapy discontinued this therapy during the course of observation (mean time to discontinuation was 383 days). The most common reasons for discontinuation were:
- Secondary loss of response
- Side effects
- Primary non-response
The Target RWE poster accepted to the RAD Conference titled ‘International observational atopic dermatitis cohort to follow natural history and treatment course: TARGET-DERM AD study design and rationale’ describes the importance of the international TARGET-DERM cohort of atopic dermatitis (AD) patients with the primary aims of:
- Characterization of AD treatment regimens
- Evaluation of response to therapy, and
- Description of adverse events
“The work presented at AIBD included several important findings while the poster presented at RAD described the TARGET-DERM methodology; each conference is a terrific, disease-specific setting for sharing this information,” said Julie M. Crawford, MD, Senior Director of Scientific and Medical Affairs.
Both Target RWE posters are in the process or have moved to manuscript next, with the TARGET-DERM methodology manuscript recently published with BMJ Open. You can find both posters on our Publications page.
About Target RWE
As the industry's best-in-class, complete real world evidence (RWE) solution, Target RWE is a distinctly collaborative enterprise that unifies real world data (RWD) sets and advanced RWE analytics in an integrated community, shifting the paradigm in healthcare for how decisions are made to improve lives.
Target RWE sources unique, connected data sets across multiple therapeutic areas representing granular data from diverse patients in academic and community settings. Our rigorous, interactive, and advanced RWE analytics extract deep insights from RWD to answer important questions in healthcare. Target RWE brings together the brightest minds in healthcare through an unmatched community of key opinion leaders, patients, and healthcare stakeholders in a collaborative and dynamic model. www.targetrwe.com
984.234.0268 ext 205
12/04/2023Overcoming Scalability Challenges in Real-World Data Processing for Transformative Patient Care
11/13/2023Real-World Evidence in Pharmaceutical Drug Development – Faster, Safer and More Relevant?
10/23/2023Leveraging Real-World Evidence with Analytics: 3 Essential Components to Capture a 360-Degree View of Your Patient Population
11/13/2023TARGET-NASH Offers Unprecedented Glimpse into Growing Public Health Concerns with Few Treatment Options
11/10/2023Target RWE Releases Important Updates on the Cirrhosis Quality Collaborative/TARGET-Liver Disease Partnership with the American Association for the Study of Liver Diseases